CMS to analyze coverage of monoclonal antibody Alzheimer's drug

By staff writers

July 14, 2021 -- The U.S. Centers for Medicare and Medicaid Services (CMS) will conduct a national coverage determination analysis of beta amyloid-directed monoclonal antibody (MoAb) treatment for Alzheimer's disease, including the new drug aducanumab.

The Alzheimer's Association applauds CMS's analysis, which would help ensure that patients who might benefit from the treatment have access. Also, the association calls on the agency to provide immediate guidance to help people navigate access to coverage as the analysis process moves forward during the next several months.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking